成都先导：9月15日召开董事会会议

Group 1 - Chengdu Xian Dao (SH 688222) held its third board meeting on September 15, 2025, to review the proposal regarding adjustments to the 2025 restricted stock incentive plan [1] - For the year 2024, Chengdu Xian Dao's revenue composition is 99.95% from scientific research and technical services, with other businesses contributing 0.05% [1] - As of the report, Chengdu Xian Dao has a market capitalization of 10.7 billion yuan [1] Group 2 - A significant breakthrough has been recognized for a new drug in China, acknowledged by both Chinese and U.S. officials for its breakthrough efficacy, generating excitement at the World Lung Cancer Conference [1]